Yoda Takeshi, Katsuyama Hironobu
Department of Public Health, Kawasaki Medical School, Kurashiki, Japan.
Department of Health and Sports Science, Kawasaki University of Medical Welfare, Kurashiki, Japan.
Hum Vaccin Immunother. 2021 Mar 4;17(3):852-856. doi: 10.1080/21645515.2020.1788309. Epub 2020 Aug 5.
Hepatitis B virus (HBV) vaccination is recommended for health-care professionals because of their frequent contact with blood. At one medical school, new students undergo HBV antibody tests upon admission, and antibody-negative individuals receive the HBV vaccine. We aimed to characterize individuals who remained antibody negative after HBV vaccination. Between 2009 and 2017, we enrolled 1064 first-year students from a medical school where their HBV antibody test and vaccination records remained. We analyzed data regarding the hepatitis B surface antibody (anti-HBs) test record during admission, vaccination record for antibody-negative participants, anti-HBs test result after completing the three vaccination doses, drug name of the vaccine used, sex, body mass index (BMI), and age. We calculated the yearly percentage of antibody-negative individuals and analyzed the characteristics of vaccine-refractory cases by logistic regression analysis. Of the 1064 participants, 999 were initially antibody negative. They were vaccinated with HBV thrice and tested for antibodies after vaccination. The average age of participants was 20.1 y, with 677 males. Although the type of vaccine has been changed since 2016, the average rate of refractoriness from 2009 to 2015 was 6.9% per year and 18.6% after 2016. Logistic regression analyses showed that sex (male vs. female; OR, 1.787), BMI (OR. 1.171), and vaccine type (genotype A vs. genotype C: OR, 3.144) were significant factors associated with antibody-negative individuals. Vaccine type differences altered the proportion of antibody-refractory individuals, with no association with age. The data on vaccine refractoriness will be continuously analyzed in the future while considering other factors.
由于医护人员经常接触血液,因此建议他们接种乙肝病毒(HBV)疫苗。在一所医学院,新生入学时会接受HBV抗体检测,抗体阴性的个体将接种HBV疫苗。我们旨在对HBV疫苗接种后仍为抗体阴性的个体进行特征描述。2009年至2017年期间,我们招募了一所医学院的1064名一年级学生,这些学生保留了他们的HBV抗体检测和疫苗接种记录。我们分析了入学时乙肝表面抗体(抗-HBs)检测记录、抗体阴性参与者的疫苗接种记录、完成三剂疫苗接种后的抗-HBs检测结果、所用疫苗的药物名称、性别、体重指数(BMI)和年龄等数据。我们计算了抗体阴性个体的年度百分比,并通过逻辑回归分析分析了疫苗难治性病例的特征。在1064名参与者中,999人最初抗体为阴性。他们接种了三次HBV疫苗,并在接种后进行了抗体检测。参与者的平均年龄为20.1岁,其中男性677人。尽管自2016年以来疫苗类型有所变化,但2009年至2015年的平均难治率为每年6.9%,2016年后为18.6%。逻辑回归分析表明,性别(男性与女性;比值比,1.787)、BMI(比值比,1.171)和疫苗类型(A基因型与C基因型:比值比,3.144)是与抗体阴性个体相关的重要因素。疫苗类型差异改变了抗体难治个体所占比例,与年龄无关。未来将在考虑其他因素的同时持续分析疫苗难治性数据。